oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2020 ( 16 )

2019 ( 86 )

2018 ( 107 )

2017 ( 126 )

Custom range...

Search Results: 1 - 10 of 12993 matches for " Mohammad Bagher Owlia "
All listed articles are free for downloading (OA Articles)
Page 1 /12993
Display every page Item
Lymphomatoid Granulomatosis with Splenomegaly and Pancytopenia
Abolhasan HALVANI,Mohammad Bagher OWLIA,Ramin SAMI
Chinese Journal of Lung Cancer , 2010,
Abstract: Lymphomatoid granulomatosis (LG) is an angiocentric lymphoproliferative disease. It usually involves lung, skin, and central nervous system, but splenomegaly and pancytopenia are the rare manifestations of the disease. We report a 15-year-old boy presented with fever, dry cough and dyspnea from two months ago, after admission patient had nodular lesions on the left leg and hepatosplenomegaly. Then he manifested neurologic signs such as seizure, aphasia and right-sided hemiplegia. Chest X-ray and CT scan revealed bilateral pulmonary nodules predominantly in lower lobes and peripheral lung fields. Laboratory exams showed pancytopenia. Skin biopsy was done, and histopathological examination and immunohistochemistry evaluation confirmed lymphomatoid granulomatosis. He was treated with steroid and cyclophosphamide but succumbed by neurologic involvement.
Ischemic Toes after Venous Thromboembolism: A Difficult Differential Diagnosis with Good Response to Combination Therapy—A Case Report
Mohammad Bagher Owlia,Ahmad Salimzadeh,Gholmhossein Alishiri,Saeed Kargar
Case Reports in Medicine , 2012, DOI: 10.1155/2012/403685
Abstract: The obliteration of the arterial vascular system of toes is considered as a potentially catastrophic event in clinical practices. In most instances, the cessation of arterial blood flow heralds a serious underlying pathology. A definite classification of some cases is somehow difficult and subject to diagnostic challenges. The aim of the present case study is to share and discuss potentially complex and multifactorial mechanisms of some acute vascular events. In this report, we deal with a 46-year-old man with a rather gradual-onset ischemia of his toe who responded favorably to a combination of pulsed glucocorticoid and anticoagulation within a week.
Erratum to “Bedtime Single-Dose Prednisolone in Clinically Stable Rheumatoid Arthritis Patients"
Mohammad Bagher Owlia,Golbarg Mehrpoor,Moneyreh Modares Mosadegh
ISRN Pharmacology , 2012, DOI: 10.5402/2012/521976
Abstract:
Bedtime Single-Dose Prednisolone in Clinically Stable Rheumatoid Arthritis Patients
Owlia Mohammad Bagher,Mehrpoor Golbarg,Modares Mosadegh Moneyreh
ISRN Pharmacology , 2012, DOI: 10.5402/2012/637204
Abstract:
Bedtime Single-Dose Prednisolone in Clinically Stable Rheumatoid Arthritis Patients
Owlia Mohammad Bagher,Mehrpoor Golbarg,Modares Mosadegh Moneyreh
ISRN Pharmacology , 2012, DOI: 10.5402/2012/637204
Abstract: Introduction. Sign and symptoms of rheumatoid arthritis have circadian rhythms and are more prominent in the morning. Timing of glucocorticoid administration may be important with respect to the natural secretion of endogenous glucocorticoids. Herein, we intended to test the hypothesis that bedtime administration of prednisolone could be more efficient in controlling signs and symptoms in patients with RA. Material and Methods. Sixty patients with stable disease were treated with single dose prednisolone at 8 a.m. for the first three months and thereafter with similar dose at 10?PM for the next three months (before-after method). We compared fatigue scores, morning stiffness and pain scores, Clinical Disease Activity Indices, erythrocyte sedimentation rates, C Reactive Protein, and profile of adverse effects. Results. The mean of morning stiffness, fatigue scores, CRP and CDAI decreased statistically when prednisolone was administrated at 10?p.m. The means of pain scores and ESR were also decreased when the patients took prednisolone at night, without significant statistical difference. Conclusion. Administration of low-dose oral prednisolone could reduce disease activity scores in morning in clinically stable patients with RA. So it could be supposed that administrating bedtime prednisolone may permit the smallest possible dose. 1. Introduction In rheumatoid arthritis (RA), a circadian rhythm of disease activity has been well documented [1]. Morning stiffness, joint pain, and swelling (one of the RA classification criteria) are worse in morning, which could be explained by diurnal variations in the metabolism or secretion of endogenous cortisol and cytokines, especially IL6 [2]. Corticotropin-releasing hormone (CRH) release leads to the pituitary production of corticotrophin (ACTH), followed by glucocorticoid secretion by the adrenal cortex. These components constitute the hypothalamic-pituitary-adrenocortical (HPA) axis, which has a circadian rhythm [3]. The ACTH level varies during the day due to its pulsatile secretion. As a result, in physiologic conditions, plasma ACTH and serum cortisol concentrations are highest at about the time of waking in the morning (at 8 AM), decrease irregularly during the day, are low in the evening, and reach their nadir after beginning sleep (at 2 AM) [4]. In RA patients, impaired cortisol secretion to ACTH has been described, supporting the concept of a relative adrenal glucocorticoid insufficiency [5]. Moreover, IL6 is also considered to be responsible for stimulating the production of acute phase of proteins, and
Erratum to “Bedtime Single-Dose Prednisolone in Clinically Stable Rheumatoid Arthritis Patients"
Mohammad Bagher Owlia,Golbarg Mehrpoor,Moneyreh Modares Mosadegh
ISRN Pharmacology , 2012, DOI: 10.5402/2012/521976
Abstract:
Dermatomyositis Sine Myositis with Membranoproliferative Glomerulonephritis
Mohammad Bagher Owlia,Roya Hemayati,Shokouh Taghipour Zahir,Mohammad Moeini Nodeh
Case Reports in Rheumatology , 2012, DOI: 10.1155/2012/751683
Abstract: Dermatomyositis (DM) is an autoimmune disease that is characterized by involvement of proximal musculature and skin. We report a 52-year-old woman with a 6-year history of dermatomyositis sine myositis, who developed lower extremity edema and proteinuria. Pathological examination of renal biopsy showed membranoproliferative glomerulonephritis. She received steroid, cyclophosphamide, and mycophenolate mofetil. Over the 9 to 10 months after the beginning of treatment, the proteinuria was improved.
Rheumatological Findings in Candidates for Valvular Heart Surgery
Mohammad Bagher Owlia,Seyed Jalil Mirhosseini,Nafiseh Naderi,Seyed Mohammad Yousof Mostafavi Pour Manshadi
ISRN Rheumatology , 2012, DOI: 10.5402/2012/927923
Abstract:
Cardiac Manifestations of Rheumatological Conditions: A Narrative Review
Mohammad Bagher Owlia,Seyed Mohammad Yousof Mostafavi Pour Manshadi,Nafiseh Naderi
ISRN Rheumatology , 2012, DOI: 10.5402/2012/463620
Abstract:
Cardiac Manifestations of Rheumatological Conditions: A Narrative Review
Mohammad Bagher Owlia,Seyed Mohammad Yousof Mostafavi Pour Manshadi,Nafiseh Naderi
ISRN Rheumatology , 2012, DOI: 10.5402/2012/463620
Abstract: Cardiovascular diseases are common in systemic rheumatologic diseases. They can be presented at the time of diagnosis or after diagnosis. The cardiac involvements can be the first presentation of rheumatologic conditions. It means that a patient with rheumatologic disease may go to a cardiologist when attacked by this disease at first. These manifestations are very different and involve different structures of the heart, and they can cause mortality and morbidity of patients with rheumatologic diseases. Cardiac involvements in these patients vary from subclinical to severe manifestations. They may need aggressive immunosuppressive therapy. The diagnosis of these conditions is very important for choosing the best treatment. Premature atherosclerosis and ischemic heart disease are increased in rheumatoid arthritis and systemic lupus erythematosus, and may be causes of mortality among them. The aggressive control of systemic inflammation in these diseases can reduce the risk of cardiovascular disease especially ischemic heart disease. Although aggressive treatment of primary rheumatologic diseases can decrease mortality rate and improve them, at this time, there are no specific guidelines and recommendations, to include aggressive control and prevention of traditional risk factors, for them. 1. Introduction Systemic rheumatic diseases are autoimmune inflammatory conditions that involve several organs, frequently involving the blood vessels and the heart. Cardiac disease may occur in patients with a definite diagnosis of a rheumatologic disorder, or may be the initial manifestation in patients with no prior diagnosis. Cardiac involvements in rheumatic diseases can show themselves in different ways from asymptomatic or mild to severe or life-threatening and are significant causes of morbidity and mortality in patients with rheumatic disorders. Rheumatologic diseases can be considered as causes of myocardial, valvular, and pericardial and conduction system abnormalities. Because of these abnormalities, it is thought that rheumatologic disorders have been associated with premature atherosclerosis leading to ischemic heart disease at young ages. The increased risk of coronary disorders cannot be solely attributed to traditional cardiovascular (CV) risk factors, and may be a result of chronic systemic inflammation from the rheumatic disease. The prevalence and importance of cardiovascular disease in rheumatologic disorders have increased in the setting of therapeutic advances. One should consider chronic inflammation as a cause of cardiac diseases in people with
Page 1 /12993
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.